The Role of Genetic Testing in Personalized Psychiatry
How pharmacogenomic testing provides adjunctive biological insights into liver enzyme metabolism and pharmacokinetic pathways to inform psychiatric prescribing.
Key Clinical Takeaways
- Pharmacogenomic testing looks at specific genes to predict how your body may process certain psychiatric medications.
- It does not diagnose mental illnesses (like depression or bipolar disorder); it provides information that can help inform, not dictate, medication choices.
- Testing uses a simple, non-invasive cheek swab.
- It may be considered for patients who have tried several medications with strong side effects or limited benefit; evidence that testing improves overall outcomes is still limited.
Beyond Trial and Error: Understanding Pharmacogenomics
Many patients arrive at Premier Psychiatry having experienced a frustrating cycle: starting an antidepressant or mood stabilizer, waiting four to eight weeks, only to navigate intolerable side effects or insufficient symptom relief.
Pharmacogenomics combines pharmacology (the study of drugs) and genomics (the study of genes). By analyzing specific genetic markers, your clinician gains information about how your liver enzymes may break down certain psychiatric medications.
What Psychiatric Genetic Testing Analyzes
The test evaluates two primary biological mechanisms:
1. Pharmacokinetics (Metabolism)
Examines cytochrome P450 (CYP450) liver enzymes (such as CYP2D6 and CYP2C19). If you are a poor metabolizer, standard doses may build up to higher plasma levels, increasing side effect risks. If you are an ultra-rapid metabolizer, your body breaks down the medication unusually quickly, which may require dosage adjustments.
2. Pharmacodynamics (Receptor Markers)
Examines gene variations that code for serotonin transporters (such as SLC6A4) and receptors (such as HTR2A). CPIC’s 2023 antidepressant guideline concluded that current evidence does not support using SLC6A4 or HTR2A results to guide antidepressant prescribing, while it does provide recommendations for some metabolism genes.
What the Test Does (and Does Not) Tell Us
Important Diagnostic & Clinical Distinction:
Genetic testing does not diagnose mental health conditions. It will not show whether you have depression, anxiety, ADHD, or bipolar disorder. Diagnosis remains a clinical discipline requiring a comprehensive psychiatric evaluation.
Furthermore, genetic testing does not guarantee that a specific medication will work. The FDA has warned that many genetic tests claiming to predict how a person will respond to specific medications, including antidepressants, may not be supported by clinical evidence, and an American Psychiatric Association workgroup concluded in 2024 that the evidence does not support using currently available combinatorial pharmacogenomic tests to select treatment for depression. Results are best used as one input about drug metabolism, not as a prediction of whether a medication will work.
How Premier Psychiatry Administers Genetic Testing
At Premier Psychiatry, genetic testing fits within an individualized care plan:
- Clinical Consultation: During your intake or a follow-up visit, your clinician reviews your medication history to decide with you whether testing may be helpful.
- Simple Swab: A swab collects cells from inside your cheek. It is quick and non-invasive.
- Laboratory Analysis: The sample is sent to the GeneSight® laboratory (CLIA-certified and CAP-accredited), which returns the results to your clinician.
- Collaborative Treatment Review: You and your clinician review the results together and consider them alongside your history when planning treatment.
Scientific References & Regulatory Guidance
- • U.S. Food and Drug Administration (FDA): Table of Pharmacogenetic Associations; and Safety Communication, “The FDA Warns Against the Use of Many Genetic Tests with Unapproved Claims to Predict Patient Response to Specific Medications” (2018).
- • American Psychiatric Association (APA): APA Workgroup on Biomarkers and Novel Treatments, “Pharmacogenomic Clinical Support Tools for the Treatment of Depression,” American Journal of Psychiatry (2024).
- • Clinical Pharmacogenetics Implementation Consortium (CPIC): CPIC Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (2023).